Arkolith/Insider Trading/TALS/Form 4

Requadt Scott

Chief Executive Officer, DirectorTalaris Therapeutics, Inc. (TALS) · full profile →Form 4 · filed Feb 2, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 31, 2021Grant(A)1K$13.00$19K451K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 1, 2022Grant(A)500K—$0500K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-22-004202) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML